Premium
Influence of Parenteral Nutrition Delivery System on the Development of Bloodstream Infections in Critically Ill Patients
Author(s) -
PontesArruda Alessandro,
Santos Maria Cecília Freitas Cesarino,
Martins Laércia Ferreira,
González Eddy René Rodriguez,
Kliger Ruben Gustavo,
Maia Marcelo,
Magnan Gisele Brocco
Publication year - 2012
Publication title -
journal of parenteral and enteral nutrition
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.935
H-Index - 98
eISSN - 1941-2444
pISSN - 0148-6071
DOI - 10.1177/0148607111427040
Subject(s) - medicine , incidence (geometry) , parenteral nutrition , sepsis , intensive care unit , central venous catheter , shock (circulatory) , septic shock , catheter , mechanical ventilation , surgery , physics , optics
Background: Parenteral nutrition (PN) is associated with an increased risk of developing bloodstream infections (BSIs) but the impact of the PN delivery system upon BSI rates remains unclear. This was an international, multicenter, prospective, randomized, open‐label, controlled trial that investigated the differences of BSIs associated with 2 different PN systems. Methods: Patients were randomly allocated in a 2:1:1 ratio to receive either PN delivered by a multichamber bag (MCB group), or by compounded PN made with olive oil (COM1 group) or with MCT/LCT (COM2 group). Blood cultures were performed to evaluate the incidence of BSIs, and catheter use data was collected to calculate CLAB and central venous catheter device use ratio (CVC‐DUR). Secondary outcomes included the development of severe sepsis/septic shock, number of intensive care unit (ICU) and hospital days, and all‐cause mortality at Day 28. Results: 406 patients were included: 202 in the MCB group, 103 in the COM1 group, and 101 in the COM2 group. Baseline characteristics were well balanced between the 3 groups, BSIs were significantly higher in patients receiving compounded PN (46 BSIs for COM1+COM2 vs 34 BSIs for MCB; p = 0.03).CLAB was higher in patients receiving compounded PN (13.2 for COM1+COM2 vs 10.3 for MCB; p < 0.0001). No differences were observed for the secondary outcomes. Conclusion: Compounded PN was associated with a higher incidence of BSIs and CLABs, suggesting that the use of MCB PN may play a role in reducing the incidence of BSIs in patients who receive PN. Trial registration number: NCT00798681.